Circio Holding ASA: Registration of share capital increase following exercise of options and settlement of RSUs

Summary by AI ^BETAClose X

Circio Holding ASA has registered a share capital increase with the Norwegian Register of Business Enterprises, bringing its new share capital to NOK 142,903,417.20, comprising 238,172,362 shares each with a nominal value of NOK 0.60. This increase is a result of the exercise of employee options and the settlement of restricted stock units for employees and board members under the company's long-term incentive program.

Disclaimer*

Oslo, 11 May 2026: Reference is made to the stock exchange announcement by Circio Holding ASA (OSE: CRNA) (the "Company") on 6 May 2026, regarding the board of directors' resolution to increase the share capital of the Company in connection with the exercise of employee options and the settlement of restricted stock units (“RSUs”) pursuant to the Company's long-term incentive program for its employees and the Company's program for RSUs for the board members.

The share capital increase has now been registered with the Norwegian Register of Business Enterprises (Nw. Foretaksregisteret). The Company's new share capital is NOK 142,903,417.20, divided into 238,172,362 shares, each with a nominal value of NOK 0.60.

About Circio
Building circular RNA expression systems for enhanced gene and cell therapies

Circio Holding ASA is a biotechnology company developing novel circular RNA expression technology for gene and cell therapy.

Circio has established a unique circular RNA (circRNA) vector expression technology for next generation RNA, DNA and viral therapeutics. The proprietary circVec platform is based on a modular genetic construct designed for efficient biogenesis of multifunctional circRNA inside target cells. The circVec platform has applications in multiple therapeutic settings, including genetic medicine, cell therapy and chronic disease. It has demonstrated 75-fold increased RNA half-life and up to 50-fold enhanced protein expression vs. conventional mRNA-based viral and non-viral vector systems, with the potential to become a new gold-standard gene expression technology. The circVec R&D activities are being conducted by the wholly owned subsidiary Circio AB in Stockholm, Sweden.